Skip to main content

Table 2 Summary of analyses: MWA versus HR

From: Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis

Outcome Number of studies included in meta-analysis Summary effect* (95% CI); P value Heterogeneity (I2 value) (%)
Primary outcome
 LTR 8 2.49 (1.19, 5.22); P = 0.016 84
Secondary outcomes
 OS (1-year) 10 1.01 (0.99, 1.03); P = 0.409 0
 OS (3-year) 10 0.94 (0.88, 0.99); P = 0.03 0
 OS (5-year) 9 0.88 (0.80, 0.97); P = 0.01 0
 IDL 5 1.13 (0.80, 1.60); P = 0.474 75
 EHM 2 1.10 (0.71, 1.72); P = 0.659 0
 Operative time (min) 3 − 58.69 (− 89.55, − 27.83); P < 0.001 94
 Intraoperative blood loss (mL) 3 − 189.09 (− 324.54, − 53.64); P = 0.006 93
 Hospital length of stay (days) 6 − 6.16 (− 8.25, − 4.07); P < 0.001 84
 DFS (1-year) 8 0.95 (0.90, 1.01); P = 0.085 39
 DFS (3-year) 8 0.78 (0.65, 0.94); P = 0.009 59
 DFS (5-year) 8 0.83 (0.58, 1.17); P = 0.284 71
 Overall complications 9 0.31 (0.19, 0.51); P < 0.001 10
 Major complications 4 0.24 (0.10, 0.61); P = 0.002 0
 Minor complications 3 0.45 (0.23, 0.90); P = 0.024 66
  1. *Risk ratio (RR) for MWA versus HR for all outcomes except operative time, intraoperative blood loss, and hospital length of stay, which are reported as the weighted mean difference (WMD). Italicized values indicate statistical significance. Point estimates and confidence intervals were calculated using a random effects model
  2. Abbreviations: CI confidence interval, DFS disease-free survival, EHM extrahepatic metastasis, HR hepatic resection, IDL intrahepatic de novo lesions, LTR local tumor recurrence, MWA microwave ablation, OS overall survival, RR risk ratio